Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics

被引：0
|
作者：
Jörg Mahlich
Kerstin Olbrich
Adrian Wilk
Antonie Wimmer
Claus Wolff-Menzler
机构：
[1] Health Economics and Outcomes Research,Düsseldorf Institute of Competition Economics (DICE)
[2] Janssen,Team Gesundheit
[3] Pharmaceutical Companies of Johnson & Johnson,Department of Psychiatry and Psychotherapy
[4] University of Düsseldorf,undefined
[5] Gesellschaft für Gesundheitsmanagement mbH,undefined
[6] Medical Affairs,undefined
[7] Janssen,undefined
[8] Pharmaceutical Companies of Johnson & Johnson,undefined
[9] University Medical Center Göttingen,undefined
[10] Georg-August-University,undefined
来源：
Clinical Drug Investigation | 2021年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：99 / 113
页数：14
相关论文
共 50 条
  • [31] The place of long-acting injectable antipsychotics in the treatment of schizophrenia
    Kane, John M.
    Rubio, Jose M.
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2023, 13
  • [32] Current and emerging long-acting antipsychotics for the treatment of schizophrenia
    de Filippis, Renato
    De Fazio, Pasquale
    Gaetano, Raffaele
    Steardo, Luca
    Cedro, Clemente
    Bruno, Antonio
    Zoccali, Rocco Antonio
    Muscatello, Maria Rosaria Anna
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (07) : 771 - 790
  • [33] Comparisons of the effects of long-acting injectable monotherapy and combination therapy of long-acting injectable treatment with oral antipsychotics on treatment retention in patients with chronic schizophrenia
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    Inoue, Yuichi
    Takaya, Atsuhiko
    ASIAN JOURNAL OF PSYCHIATRY, 2019, 39 : 112 - 113
  • [34] Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia
    Olivares, Jose M.
    Pinal, Beatriz
    Cinos, Carmen
    NEUROPSYCHIATRY, 2011, 1 (03) : 275 - 289
  • [35] ANTIPSYCHOTIC ADHERENCE AND PERSISTENCE AMONG PATIENTS WITH SCHIZOPHRENIA RECEIVING LONG-ACTING INJECTABLES VERSUS ORAL FORMULATIONS: A SYSTEMATIC REVIEW
    Chen, S.
    Zhang, H.
    Zhang, S.
    Barner, J. C.
    VALUE IN HEALTH, 2022, 25 (07) : S465 - S466
  • [36] Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics
    Ankit Shah
    Lin Xie
    Furaha Kariburyo
    Qisu Zhang
    Mugdha Gore
    Advances in Therapy, 2018, 35 : 1994 - 2014
  • [37] Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics
    Shah, Ankit
    Xie, Lin
    Kariburyo, Furaha
    Zhang, Qisu
    Gore, Mugdha
    ADVANCES IN THERAPY, 2018, 35 (11) : 1994 - 2014
  • [38] Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review
    Zhornitsky, Simon
    Stip, Emmanuel
    SCHIZOPHRENIA RESEARCH AND TREATMENT, 2012, 2012
  • [39] A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal
    Suzuki, Takefumi
    EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (02) : 253 - 264
  • [40] Oral versus long-acting injectable antipsychotics in schizophrenia spectrum disorders: A systematic review of patients' subjective experiences
    Aprile, Sofia Francesca
    Rodolico, Alessandro
    Di Francesco, Antonio
    Varrasi, Sofia
    Bighelli, Irene
    Castellano, Sabrina
    Signorelli, Maria Salvina
    Leucht, Stefan
    Caraci, Filippo
    PSYCHIATRY RESEARCH, 2025, 348
12345